Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Sung Gwe Ahn1,3 · Seon-Kyu Kim2 · Jonathan H. Shepherd3 · Yoon Jin Cha5 · Soong June Bae1 · Chungyeul Kim6 · Joon Jeong1 · Charles M. Perou3,4

Received: 19 January 2021 / Accepted: 10 March 2021
© The Author(s) 2021

Abstract

Purpose The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer (TNBC). We strove to understand the biological, genomic, and clinical characteristics associated with SP142 PD-L1 positivity in TNBC patients.

Methods Using 149 TNBC formalin-fixed paraffin-embedded tumor samples, tissue microarray (TMA) and gene expression microarrays were performed in parallel. The VENTANA SP142 assay was used to identify PD-L1 expression from TMA slides. We next generated a gene signature reflective of SP142 status and evaluated signature distribution according to TNBC type and PAM50 subtypes. A SP142 gene expression signature was identified and was biologically and clinically evaluated on the TNBCs of TCGA, other cohorts, and on other malignancies treated with immune checkpoint inhibitors (ICI).

Results Using SP142, 28.9% of samples were PD-L1 protein positive. The SP142 PD-L1-positive TNBC had higher CD8+ T cell percentage, stromal tumor-infiltrating lymphocyte levels, and higher rate of the immunomodulatory TNBC type compared to PD-L1-negative samples. The recurrence-free survival was prolonged in PD-L1-positive TNBC. The SP142-guided gene expression signature consisted of 94 immune-related genes. The SP142 signature was associated with a higher pathologic complete response rate and better survival in multiple TNBC cohorts. In the TNBC of TCGA, this signature was correlated with lymphocyte-infiltrating signature scores, but not with tumor mutational burden or total neoantigen count. In other malignancies treated with ICIs, the SP142 genomic signature was associated with improved response and survival.

Conclusions We provide multi-faceted evidence that SP142 PDL1-positive TNBC have immuno-genomic features characterized as highly lymphocyte-infiltrated and a relatively favorable survival.

Keywords Triple-negative breast cancer · SP142 PD-L1 · Tumor-infiltrating lymphocytes · Immune-check point inhibitors

Introduction

The prognosis of triple-negative breast cancer (TNBC) patients remains inferior to other clinical subtypes of breast cancers, in part because it lacks ER, PgR, and HER2.
which can be targeted by endocrine therapy or anti-HER2 therapy [1]. Recent studies have revealed that TNBC has more immunogenomic features including increased tumor-infiltrating lymphocytes (TILs), increased expression of immune-related molecules and signatures, and higher tumor mutational burden (TMB), amongst mammary malignancies [2, 3]. Therefore, targeting programmed death 1 (PD-1) or its ligand (PD-L1), in combination with chemotherapy, is an emerging approach to offer clinical benefits in both early and advanced TNBC [4–9].

Among recent breast cancer trials with immune targeting drugs, the IMPASSION-130 trial demonstrated that the anti-PD-L1 monoclonal antibody atezolizumab plus nab-paclitaxel prolonged progression-free survival (PFS) in patients with metastatic TNBC [5]. Furthermore, the researchers showed that overall survival (OS) was improved by adding atezolizumab in the PD-L1-positive subgroup, which was defined by PD-L1 expression on immune cells using the SP142 antibody-based immunohistochemistry assay. Based on these findings, the Food and Drug Administration approved the use of atezolizumab for patients with PD-L1-positive metastatic TNBC [10], with the SP142 PD-L1 assay as a companion diagnostic. In addition, a clinical trial conducted in patients with early TNBC showed that PD-L1-positivity was a strong predictor for pathological complete response (pCR) [11].

These findings led us to investigate the clinical and genomic characteristics associated with SP142 PD-L1+ TNBC, with the hypothesis that PD-L1 protein expression might be associated with better survival outcome in the absence of immunotherapies. In this study, we evaluated PD-L1 expression by SP142 assay on TNBC tissue microarray (TMA), investigated clinicopathological features of PD-L1+ cases, and performed genomic analyses to develop a SP142 gene expression signature. Clinical and genomic aspects of this signature were further assessed in The Cancer Genome Atlas (TCGA) [12] and other TNBC cohorts. Finally, we tested the SP142 signature in the cohorts of other malignancies treated with immune-check point inhibitors (ICIs).

Patients and tumor samples

Formalin-fixed paraffin-embedded (FFPE) TNBC tumor samples were selected from the database of breast cancer patients treated between January 1999 and December 2014 at Gangnam Severance Hospital, Yonsei University Medical College, Seoul, Korea. Tumor cellularity was defined as the percentage of invasive tumor nuclei and was over 80% in all breast cancer specimens. Exclusion criteria for patient samples included: samples only exhibiting in situ carcinoma of the breast, bilateral breast cancers, as well as non-epithelial origin breast cancer, such as phyllodes tumor, sarcoma, or lymphoma.

TNBC was defined by the lack of ER, PR and HER2 based on immunohistochemical (IHC) stain. For routine IHC studies, ER (1:100 clone 6F11; Novocastra, Newcastle upon Tyne, UK), PR (clone 16; Novocastra), HER2 (4B5 rabbit monoclonal antibody; Ventana Medical Systems, Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, Glostrup, Denmark) were stained using formalin-fixed paraffin-embedded tissue sections as previously described [13, 14]. ER positivity and PR expression on immunohistochemistry were defined according to the modified Allred system. In our study, ER and PR positivity were defined as an Allred score ≥ 3. The HER2 status was considered positive with a score of 3+ and negative with a score of 0 or 1+ [15]. Tumors with a score of 2+ were sent for fluorescent in situ hybridization analysis according to the protocol given by the supplier (PathVysion kit; Vysis, Downers Grove, IL, USA or HER2 inform; Ventana). A total of 149 TNBC subjects were investigated in our study.

Tissue microarray, SP142 PD-L1 assay, and other studies

TMA paraffin blocks were generated as previously described using an Accu Max Array tissue-arraying instrument (Petagen, Inc., Seoul, Korea) [16]. In each samples, a single core was punched in the area showing invasive tumor nuclei was comprised ≥ 80% to construct the TMA slides. PD-L1 expression, stromal TILs, and CD8 percentage were assessed from TMA slides. PD-L1 expression was determined using VENTANA PD-L1 SP142 assay, which is a qualitative IHC assay using rabbit monoclonal anti-PD-L1 clone SP142 [5, 17]. PD-L1 protein on tumor-infiltrating immune cells was assessed in each TMA slide stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. The scoring of PD-L1 positivity followed the guidelines and where pathologist (YJC) confirmed the tumor-infiltrating immune cells which

Methods

Ethics statement

The institutional review board (IRB) of Gangnam Severance Hospital, Yonsei University, Seoul, Korea, approved the study in accordance with good clinical practice guidelines and the Declaration of Helsinki (local IRB approval number: 3-2013-0268). The need for informed consent was waived because of the retrospective design.
were morphologically consistent with lymphocytes, macrophages, dendritic cells, and granulocytes by H&E staining. Then, PD-L1 expression on tumor-infiltrating immune cells was quantified in intra-tumoral and peri-tumoral stromal area. Areas with neutrophilic debris and necrotic debris was excluded from scoring. Presence of discernible PD-L1 staining of any intensity covering ≥ 1% of tumor area was considered as PD-L1 positive [5, 9]. Benign tonsil tissue was used as a positive (lymphocytes and macrophages in germinal center, reticulated crypt epithelium) and negative (inter-follicular lesion and overlying squamous epithelium) controls. PD-L1 expression values for each subject are presented as Supplementary Table S1A. The PD-L1 SP142 assay was performed blindly with no clinical information being given to the examiner.

The TIL counts were measured as previously described [13, 18, 19]. TILs were scored according to the standardized methodology proposed by the international TIL Working Group [20]. All mononuclear cells, including lymphocytes and plasma cells, but not polymorphonuclear leukocytes, were counted. The area outside the tumor border, around the intraductal component, and normal lobules were excluded. For each case, the TIL counts were reported as a percentage. CD8 percentage among immune cells was obtained using an anti-CD8 rabbit monoclonal antibody (SP57, Ventana).

**RNA extraction, Affymetrix microarray, and data analysis**

Total RNA was isolated using Qiagen RNeasy FFPE kit (Qiagen, Hilden, Germany) according to the manufacturers’ instructions. RNA samples extracted from FFPE tissues were analyzed in terms of RNA concentration and purity using NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) [21]. Briefly, double-stranded DNA was synthesized using One-cycle cDNA Synthesis Kit (Affymetrix) followed by purification with GeneChip Sample Cleanup Module (Affymetrix). The double-stranded DNA was used as template for the in vitro transcription using Gene Chip IVT PLUS Reagent Kit (Affymetrix), which yields biotinylated cRNA. The purified biotin-labeled target cRNA was then segmented into short sequences. The HG-U133_PLUS_2 microarrays (Affymetrix) were directly loaded with 200 µl of hybridization cocktail solution and then placed in Genechip Hybridization Oven 640 (Affymetrix) rotating at 60 rpm at 45 °C for 16 h. After hybridization, the arrays were washed on Genechip Fluidics Station 400 (Affymetrix) and scanned using Genechip. The microarray data were visually inspected for physical damage and background noise. Datasets of all probes were normalized using 100 housekeeping genes in mask files of U-133_PLUS_2.0 to a means intensity of 2000 before further date processing.

The gene expression data were normalized by the quantile method, log2 transformed, and median centered across genes and samples. A hierarchical clustering analysis was carried out using Cluster 3.0 [22] and Java Tree View Software. Significance analysis of microarrays with false-discovery rate of 5% was used to identify SP142 PD-L1 related genes and gene signatures [23]. We next applied a collection of 633 known gene signatures, representing multiple biological pathways and cell types, to the median centered and standardized gene expression matrix [24].

Gene expression signatures were calculated as the median expression of all the genes in the signature as published [25]. Univariable and multivariable analyses were performed using standardized signature scores in R-studio using the Cox regression hazard model. Heat-map and PCA plot were used in analysis and DAVID (The Database for Annotation, Visualization and Integrated Discovery) tool was used in functional analysis [26, 27].

**TNBCtype and PAM50 assay**

Our RNA dataset was uploaded in the website (http://cbc.mc.vanderbilt.edu/tNBC/) [28], and the TNBCtypes were obtained for each subjects [29]. For PAM50 intrinsic subtypes, we first applied a new HER2/ER subgroup-specific gene normalization method [30], followed by the PAM50 predictor [31]. For each sample, we calculated the correlation coefficient to the PAM50 centroids (Basal-like, HER2-Enriched, Luminal A, Luminal B and Normal-like signatures, respectively) [32].

**External gene expression data analysis**

TCGA RNA-seq data were collected as previously described [12, 33]. Samples were limited to TNBC tumors defined by IHC examination. TMB, total neoantigen count, and lymphocyte-infiltration signature score for each subject in the TCGA cohort were determined from a previous publication [34]. RNA-seq data for NCT01560663 is published [35]. Microarray and variant data for the METABRIC cohort [36], was obtained from cBioPortal. RNA-seq data from SCAN-B was downloaded from GEO: GSE96058 [37]. For this study, non-TNBC samples in METABRIC and SCAN-B were excluded.

In urothelial carcinoma, raw sequencing data required for RNA-seq analyses have been deposited to the European Genome-Phenome Archive under accession number EGAS00001002556 [38, 39]. In melanoma, the RNA-seq data are deposited in the European Nucleotide Archive (ENA) [40], under accession number PRJEB23709. For RNA-seq datasets, genes with no reads across any of the samples were removed. Raw RNA-seq data were aligned to reference genome hg38 and quantified using a STAR-Salmon.
pipeline as previously described [41]. Salmon gene-level counts were upper quartile normalized. Genes with an average expression less than 10 were filtered from the dataset.

**Statistical analyses**

The distributions of non-parametric variables were compared using the Mann–Whitney U test. Survival curves were constructed using the Kaplan–Meier product limit method and compared between subtypes with the log-rank test using open-to-public datasets for which DFS, RFS, PFS, and OS results are available. In the training set, the cut-off point of the SP142 gene signature score was obtained using the time-dependent ROC curve. In the cohort of SCAN-B, interaction tests were used to explore differential effects between dichotomized PD-L1-signature score status and chemotherapy treatment in relation to OS. Cox proportional hazard regression model adjusted for available prognostic clinical covariates such as stage was performed to calculate hazard ratios using 95% confidence intervals. Variables showing a statistical significant difference in the univariate analysis were entered in the multivariable analysis. Survival analyses were performed using the R package survival. All statistical analyses were performed using the R software (https://www.r-project.org; version 3.6.1) and the GraphPad Prism. A P-value <0.05 was considered statistically significant.

**Data and code availability**

The published article includes all datasets and code generated in this study. The dataset of 149 TNBC patients generated during this study are available at GEO Datasets: GSE135565 and GSE157284. Newly generated dataset for the current study are available at the NCBI GEO database under accession numbers GSE157284 with the following secure token: qjexicmuldkxjmr. To access the dataset, the editors or reviewers should access the GEO website (https://www.ncbi.nlm.nih.gov/geo/) and insert these secure tokens.

**Results**

**Clinical and immunological characteristics of SP142 PD-L1-positive TNBC**

To begin to explore the biology and clinical associations of PD-L1 protein expression in TNBC, we collected a set of 149 tumors from which we created TMAs and performed DNA microarray-based gene expression profiling using Affymetrix microarrays. Baseline characteristics of the study population is summarized in Supplementary Table S1B-C. All tumors were treatment-naive. SP142 PD-L1 expression was successfully determined using these TMAs, and showing a rate of PD-L1+ tumors of 28.9% (43/149; Fig. 1a, Representative images in Fig. 1b).

From the DNA microarray gene expression data, we identified the “TNBC-Type” molecular classification [29] for each subject (Fig. 1c, left). When we compared “TNBC-Types” according to PD-L1-positivity, the immunomodulatory subtype had the highest rate of PD-L1 positivity (57.1%), whereas the other subtypes had PD-L1-positivity rates of 10 to 30%. PAM50 subtypes were also evaluated in relation to PD-L1 expression and although this comparison was not significant, all PD-L1+ subjects had basal-like tumors (Fig. 1c, right). Next, we noted that PD-L1+ TNBC had significantly higher mean CD8+ cell percentage than PD-L1-negative TNBC (Fig. 1d). In addition, PD-L1+ TNBC had higher average of TIL counts compared to PD-L1-negative TNBC (Fig. 1e).

In survival analyses, we only included non-metastatic TNBCs and excluded one case with missing survival data, leaving 145 subjects available; most of these patients received adjuvant chemotherapy (95%), but none of them were treated with anti-PD-1/PD-L1 inhibitors. The recurrence-free survival (RFS) was significantly prolonged in TNBC patients with PD-L1+ compared to those without PD-L1 (Fig. 1f). In univariable analysis, stage and PD-L1 status were significant prognostic factors (Supplementary Table S1D). In multivariable analysis, PD-L1+ subjects tended to have a better RFS compared to PD-L1-negative (Supplementary Table S1D).

**Gene signature for SP142 PD-L1(+) TNBC**

To begin to explore the possible associations of gene expression patterns with PD-L1 protein expression, we first noted that mean PD-L1 mRNA expression was not significantly different by SP142 PD-L1 protein assay status (Fig. 2a). Thus, we conducted supervised analyses according to PD-L1 protein positivity to identify a gene expression pattern associated with SP142 PD-L1 in TNBC. A two-class significance analysis of microarrays (SAM) [23] supervised analysis identified 94 highly expressed genes in PD-L1+ compared to those without PD-L1 (Fig. 1f). In univariable analysis, stage and PD-L1 status were significant prognostic factors (Supplementary Fig. S1). A majority of this gene cluster, which is henceforth referred to as SP142 signature, consisted of immune-related genes including immunoglobulins, major histocompatibility genes, and chemokines. To better understand the biological functions underlying the SP142 signature, we explored the gene ontology (GO) associated with this 94 gene set. This analysis strongly implicated a response of the immune system, largely mediated through adaptive immunity (Supplementary Table S2). The extent of lymphocyte activity in PD-L1+ patients is well illustrated by a heatmap showing expression of the 21 genes associated with the
GO term “lymphocyte mediated immunity (GO:0002449)” and PD-L1 mRNA levels (Fig. 2b).

We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. 2c). Next, we tested the prognostic value of SP142 signature. The continuous SP142 signature score was prognostic for RFS (HR 0.535, 95% CI 0.328–0.872) on this set of 145 non-metastatic TNBC patients. To utilize the SP142 signature as a prognostic categorical value, the time-dependent receiving operating characteristic (ROC) curve in relation to RFS was used to identify the optimal cutoff (Supplementary Fig. S2A). As a result, the top two-thirds were selected for the better RFS group versus the bottom third. Biologically, cases with top two-thirds of SP142 signature score had higher CD8 and TIL counts than those with bottom one-third (Supplementary Fig. S2B-C). Based on these findings, we classified our patients into two groups by SP142 signature; top two-thirds and bottom one-third. This assignment rate also reflects the findings of a recent clinical trial showing the PD-L1-positive rate as 56% in early TNBC [11].

The top two-thirds group had a significantly higher rate of PD-L1+ tumors (Fig. 2d), as was expected. When survival analyses were performed between these groups, we found that patients in the top two-thirds had a superior RFS when compared to patients in the lowest third for SP142 signature (Fig. 2e). Multivariable analyses including stage further supported the independent prognostic value of SP142 signature (Table 1). In contrast, continuous or categorical values of PD-L1 mRNA levels alone were not associated with RFS in the same set (Supplementary Fig. S3), indicating that SP142 signature was a better prognostic factor than PD-L1 protein expression in infiltrating immune cells (which only trended in multivariable analyses), or PD-L1 mRNA levels on this set.

Clinical value of SP142 signature in early TNBC

We next addressed the possible clinical value of the SP142 signature in early TNBC with respect to pCR and survival outcomes. First, we used published data from a TNBC cohort of 93 patients undergoing preoperative docetaxel/
Fig. 2 An RNA expression-based SP142 gene signature. a PD-L1 mRNA expression in breast tumor samples partitioned by SP142 PD-L1 status (Mann–Whitney U test). b A heat-map clustering breast tumors with 21 genes of the “Lymphocyte Mediated Immunity” signature. The rows indicate individual genes, and the columns indicate each sample. PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test).
carboplatin chemotherapy (NCT01560663) [42]. The SP142 signature-high subset of patients had a higher pCR rate (Fig. 3a), and when analyzed as a continuous score, patients with a pCR had a significantly higher SP142 scores (Fig. 3b). These findings suggest that a high SP142 signature might be associated with a higher likelihood of response to neoadjuvant chemotherapy in TNBC.

To test a relationship between SP142 signature and adjuvant chemotherapy responsiveness, we used RNA sequencing data in TNBC samples from the Sweden Cancerome Analysis Network-Breast Initiative (SCAN-B) cohort [37]. First, patients with higher SP142 signature had significantly better OS (Supplementary Fig. S4A), which was even more significant when the patient set was limited to TNBC patients receiving chemotherapy (Supplementary Fig. S4B). When we classified the patients into four groups by SP142 signature and chemotherapy treatment, chemotherapy improved OS in the SP142 top two-thirds group whereas it did not for those in the SP142 signature bottom one-third group (Fig. 3c). The interaction test between chemotherapy and dichotomized SP142 signature status was significant \( (P_{interaction} = 0.026) \), however, we acknowledge that this is not a randomized trial, and thus further testing is warranted.

Lastly, we evaluated the prognostic value of SP142 signature in another non-metastatic TNBC cohort from Molecular Taxonomy of Breast Cancer International Consortium (the METABRIC cohort) [37]. In this patient subset, both disease-free survival (DFS) and OS were superior in the SP142 signature top two-thirds group than in the lowest third group (Fig. 3d, e).

### Immunologic characterization for SP142 signature using TCGA

Next, we applied the SP142 signature to TNBC from TCGA. We divided tumors into two groups as the top two-thirds and bottom third using SP142 signature. We compared lymphocyte infiltration-signature score [43] between these two group, revealing that lymphocyte-infiltration signature score (as determined by the TCGA immune Pan-Cancer analysis) was significantly increased in SP142 signature-high patients, consistent with the increased TIL counts that were noted in SP142 PD-L1+ TNBC (Fig. 4a). We investigated whether differences in somatic mutation or neoantigen burden could explain the differences between these patient subsets, however, neither of these measures differed between groups (Fig. 4a) and strong correlations were only found between SP142 signature and lymphocyte-infiltrating score or TMB and total neoantigen count (Fig. 4b).

To further validate the biological implications of the SP142 signature, we examined the possible association of this signature when compared to 633 previously published gene signatures [24, 44]. Using SAM analysis provided additional evidence of the strong association between the SP142 gene signature and an active immune response where we found 12 immune pathway-enriched signatures with at least fourfold increase in the SP142 signature top two-thirds samples (Fig. 4c and Supplementary Table S3).

### SP142 signature in other malignancies treated with ICIs

SP142 is an assay used to select cancer patients to receive immune checkpoint inhibitors, and given that no publically available TNBC ICI-treated data set exists, we turned to other tumor types to evaluate the relationship between the SP142 signature and ICI responsiveness. First, we tested our gene signature on a metastatic urothelial carcinoma cohort treated with atezolizumab [38, 39]. Comparison of mean SP142 signature by response to atezolizumab found that patients that experienced a complete response (CR) showed the highest score (Fig. 5a). Also, in the group with top one-third SP142 signature, the CR rate was higher, and the rate of progressive disease (PD) was lower, than in either the middle or bottom one-third groups (Fig. 5b).

In this cohort, PD-L1 expression on immune cells (IC) was assessed by the SP142 assay, which is identical to the assay used in our 149 TNBCs, though the urothelial carcinoma cohort was score as IC0 (<1%), IC1 (≥1% and <5%), or IC2/3 (≥5%). The SP142 signature

| Table 1. The Cox regression hazard model with SP142 signature and stage |
|---------------------------------|-----------------|-----------|---|
|                                | HR 95% CI       | P         | HR 95% CI       | P         |
| SP142 signature                | 0.026           |           | Bottom one      | 1          |
| Continuous                      | 0.546 0.321–0.930| 0.345     | 0.463 0.215–0.996| 0.352     |
| Stage                           |                |           | Top two         |            |
| I                               | 1              |           | II              | 1          |
| II                              | 1.647 0.585–4.636| <0.0001   | 1.638 0.579–4.636| 0.352     |
| III                             | 7.639 2.551–22.876| <0.0001   | 8.081 2.696–24.223| <0.0001   |
Fig. 3 Clinical value of SP142 signature in TNBC. a In the Madrid cohort, (NCT01560663), pathologic complete response (pCR) rate was higher in the SP142 signature top two-thirds group (Chi-square test). b SP142 signature score was significantly higher in the pCR group than in non-pCR group (unpaired T-test). c Overall Survival (OS) in TNBC from SCAN-B, with patients classified by SP142 signature and chemotherapy treatment status. Patients in the SP142 signature top two-thirds group that received chemotherapy had better OS (the log-rank test). The interaction test between chemotherapy treatment and dichotomized SP142 signature status was significant (P_{interaction} = 0.026). d Disease-free, and e overall survival in TNBC patients of the METABRIC cohort. The SP142 signature top two-thirds group had significantly better prognosis (log-rank test).
The lymphocyte-infiltrating signature score was significantly higher in the top two-thirds SP142 signature group than in the bottom one-third group (Mann–Whitney U test). Tumor mutational burden (middle) and total neoantigen count (right) did not significantly differ between the top two-thirds and bottom one-third SP142 signature groups (Mann–Whitney U test). b The SP142 signature score shows strong correlation with the lymphocyte-infiltration score, but not with correlated with total mutation burden (TMB) or total neoantigen count. TMB and total neoantigen were also correlated (Pearson’s R-test). The numbers in the graph indicate Spearman rank correlation coefficients. c Heat-map displaying immune-related gene signatures with > fourfold increase between SP142 signature top two-thirds and bottom one-third groups (SAM analysis).

Lastly, we evaluated our SP142 signature in a melanoma cohort treated with ICIs [40, 45]. This cohort consisted of
Fig. 5 SP142 signature in other malignancies treated with immune check-point inhibitors (ICIs). a–d In metastatic urothelial carcinoma patients treated with atezolizumab, a SP142 signature score in patients partitioned by treatment response (PD=progressive disease, SD=stable disease, PR=partial response, CR=complete response). The complete response (CR) group showed the highest mean SP142 signature score (one-way ANOVA test). b Response rates in patients partitioned by SP142 signature scores tertiles. The CR rate was higher, while PD was lower in top one-third than in either middle or bottom one-third groups (the Chi-square test). c SP142 signature score in the subsets of patients by VENTANA SP142 assay classification (IC0=PDL1 expressing immune cells < 1%, IC1 (≥ 1% and < 5%), IC2/3 (≥ 5%)). SP142 score showed an increasing pattern according to the IC groups (one-way ANOVA test, *P* < 0.001; unpaired *T*-test between IC0 and IC1, *P* < 0.0001; unpaired *T*-test between IC1 and IC2/3, *P* < 0.0001). d Overall survival (OS) of patients grouped with the top one-third SP142 signature score versus the bottom two-thirds (log-rank test). e, f In melanoma patients treated with immune-check point inhibitors, progression-free (e), and overall survival (f) are significantly better for the group of patients in the top two-thirds of SP142 signature score relative to the lowest one-third group (log-rank test).
73 patients treated with either anti-PD-1 therapy or combination blockade of PD-1 and CTLA-4 (Supplementary Table S4A). A continuous SP142 signature was prognostic for both PFS and OS (Supplementary Table S4B). Further survival analyses showed that the top two-thirds had a superior PFS and OS compared to bottom one-third patients (Fig. 5e, f).

**Discussion**

In this study, we investigated the clinical and genomic characteristics of SP142 PD-L1+ TNBC relative to SP142 PD-L1-negative TNBC. Our findings demonstrate that SP142 PD-L1+ tumors have more immunogenic traits, including high TILs by H&E, higher CD8 counts by IHC, enrichment of immune TNBC genomic subtype and showed elevated immune gene signatures at the gene expression level. Since several lines of evidence suggested that the SP142 assay detects more immune cells but fewer tumor cells compared to other PD-L1 assays [46, 47], and thus it is expected that SP142-positive TNBCs would be enriched with TILs, CD8+ cells, and other immune features, and they were. Intriguingly, PD-L1 mRNA expression level did not differ according to SP142 PD-L1 status. Despite a few earlier studies showing that PD-L1 mRNA was correlated with PD-L1 expression by SP142 assay in various malignancies [48–50], the recent study conducted in TNBC consistently showed that the levels of PD-L1 mRNA were not statistically significantly different between the SP142-based categorical value (IC ≥ 1 versus IC < 1) [51]. In addition, another study reported that the protein expression level of PD-L1 in tumor and immune cells using SP142 assay was significantly lower than in other assays [52]. Association between SP142-detected PD-L1 expression on immune cells and PD-L1 mRNA level should be further evaluated and may vary according to tumor/anatomic site as well.

Further genomic analyses elucidated that multiple immune-related genes were enriched in SP142 PD-L1-positive tumors. By generating a SP142 signature, we were able to classify TNBC tumors from additional datasets that had not had PD-L1 IHC classification, thus showing that our gene signature classification provided meaningful prognostic information on multiple TNBC cohorts. In addition, we showed that on the 149 patient TNBC set, the PD-L1 signature was a better prognostic factor than SP142 protein expression, or PD-L1 mRNA expression, noting that this is a training set exercise for the SP142 signature.

In addition, the SP142 signature was biologically validated using RNAseq data of TCGA-TNBC. This genomic study showed that the SP142 signature was correlated with lymphocyte-infiltration signature but not associated with TMB or neoantigen count, indicating that immunogenicity of TNBC arises mainly from lymphocytes-infiltrated microenvironment. In addition, TNBCs with high SP142 signature exhibit increased expression of many other immune gene signatures compared to those with low-SP142 signature. Our findings are consistent with a prior study showing that the rate of high TMB tumors in TNBC is less than 10%, while the frequency of high T cell-inflamed TNBC samples is about 50% [2]. Collectively, our data indicates that increased level of lymphocyte infiltration is a major factor contributing to SP142 PD-L1 positivity in TNBC.

A hypothesis based upon the SP142 signature is the ability to distinguish TNBC patients that are likely to respond to combined ICIs and chemotherapy, and to do so objectively and in a quantitative fashion. Because a prior study suggested that a T cell-inflamed gene signature might be potential biomarker responding to pembrolizumab in TNBC [2], investigating the SP142 signature as a predictive biomarker for PD-1/PD-L1 inhibitors is a promising future study.

This line of investigation is further strengthened by our evaluation of the SP142 signature in urothelial carcinoma, and melanoma cohorts, in which the patients were treated with ICIs. In metastatic urothelial carcinoma, the SP142 signature was associated with CR to atezolizumab and correlated with the level of PD-L1 expression on immune cells. In both cohorts, continuous or categorical SP142 signature was associated with a better survival outcome; however, we note the use of the top one-third of SP142 scores to differentiate survival in urothelial carcinoma, as opposed to the top two-thirds used in TNBC and melanoma. This is likely attributable to differences in biology among various malignancies. Nonetheless, these findings suggest that the SP142 signature may be a valuable biomarker for ICI response in TNBC as well as other cancers, however, tumor type specific cutpoints may be required for optimal implementation.

Clinically, we recognized that PD-L1-positive TNBCs tended to have a better RFS than PD-L1-negative TNBC. The positive result showing PD-L1-positivity detected by standardized SP142 assay as a strong predictor for pCR in early TNBC [11] supports the notion that PD-L1 positivity on intra-tumoral immune cells is a favorable prognostic factor. It is known that an increment of pCR often correlates with better survival outcome in TNBC [53], suggesting that patients with SP142 PD-L1 expression might have a better outcome than those without expression; further analyses are needed to confirm this hypothesis.

These results demonstrate potential clinical value of the SP142 signature for pCR and survival in TNBCs, with the important implication that a high SP142 signature is associated with a higher likelihood of response to chemotherapy based on the neoadjuvant and adjuvant cohorts tested (Fig. 3a–d). Taken together, our survival analyses suggest consistently that the subjects identified by SP142 PD-L1 assay, or SP142 gene signature, have a more favorable
prognosis among TNBC patients. Consistent with our results, a body of evidence already showed that high TIL-tumors have better outcome in TNBC [54–56].

A major caveat of our study is that we evaluated PD-L1 expression using TMA. Since the SP142 system evaluates PD-L1 expression on immune cells, contiguous peritumoral stroma could be investigated using the whole slide, but not on TMAs. Core extraction for TMAs focuses primarily on invasive tumor components with a criteria of high cellularity (> 80%), making it possible that peritumoral stroma might not be fully evaluated in some cases, thereby increasing the potential for false negative cases in our study. This is a potential reason why our PD-L1 positive rate of 29% may be lower than published atezolizumab studies, which showed the rate as 41% in metastatic [5] or 56% in early TNBC [11]. Nevertheless, the PD-L1+ samples identified in this study represent true positive cases in this context, thus our findings likely reflect genuine characteristics of those tumors. Given that the primary goal of this study was to explore the biological and clinical traits of SP142+ TNBC, validating the true clinical utility of SP142 PD-L1 expression or SP142 genomic signature is beyond the scope of this study, but clearly the next step for this signature.

In conclusion, we provide multi-faceted evidence that SP142 PDL1+ TNBC have immuno-genomic features characterized as highly lymphocyte-infiltrated and a relatively favorable survival amid TNBC. In addition, SP142 genomic signature might provide information to identify immunogenic tumors making up as much as two-thirds of TNBC. These results enhance our understanding about immunogenicity of TNBC and lay the groundwork for further studies integrating IHC and gene expression immune information for selecting patients to receive PD-1/PD-L1 target therapies.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10549-021-06193-9.

Acknowledgements This work was supported by funds from the Basic Science Research Program through the NRF (NRF-2019R1C1C1002830), a Grant (HI14C3396) by Ministry of Health & Welfare, Republic of Korea, and by the Susan G. Komen Foundation (CMP) and the Breast Cancer Research Foundation (CMP).

Author contributions SGA, SKK, CK, JS, and CMP handled the related genomic data collection. SGA, SKK, and CMP designed the genomic analyses. SGA, YJC, BSJ, and JJ collected tumor samples. YJC read the pathologic findings. SGA, SKK, and CMP contributed to the analysis of the genomic and clinical data. SGA and SKK performed the statistical analyses. SGA, SKK, JJ and CMP interpreted the data and all contributed to the writing of the manuscript.

Funding This work was supported by funds from the Breast Cancer Research Foundation, the Basic Science Research Program through the NRF (NRF-2019R1C1C1002830), a grant (HI14C3396) by Ministry of Health & Welfare, Republic of Korea, and by the Susan G. Komen Foundation.

Data availability Further information and requests for materials may be directed to the corresponding author Charles M Perou. (cperou@med.unc.edu).

Code availability The published article includes all datasets and code generated in this study. The dataset of 149 TNBC patients generated during this study are available at GEO Datasets: GSE135565 and GSE157284. Newly generated dataset for the current study are available at the NCBI GEO database under accession numbers GSE157284 with the following secure tokens: qjxcmuldkxjm. To access the dataset, the editors or reviewers should access the GEO website (https://www.ncbi.nlm.nih.gov/geo/) and insert these secure tokens.

Declarations Conflict of interest The following authors or their immediate family members indicated a financial interest. Equity ownership: Charles M Perou, Bioclassifier. Income: Charles M Perou, royalties from PAM50 breast cancer gene patent application; Intellectual Property: Charles M Perou, PAM50 breast cancer gene patent(s). The other authors have no conflict of interest.

Ethical approval The institutional review board (IRB) of Gangnam Severance Hospital, Yonsei University, Seoul, Korea, approved the study in accordance with good clinical practice guidelines and the Declaration of Helsinki (local IRB Approval Number: 3-2013-0268). The need for informed consent was waived because of the retrospective design.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389
2. Cristescu R, Mogg R, Ayers M et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. https://doi.org/10.1126/science.aar3593
3. Shah SP, Roth A, Goya R et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399. https://doi.org/10.1038/nature10933
4. Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821. https://doi.org/10.1056/NEJMoa1910549
5. Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl
6. Gianni L, Huang C-S, Egle D et al (2020) Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIpaPDL1 Michelangelo randomized study. Cancer Res 80(4 Supplement):GS3-04–GS03-04. https://doi.org/10.1158/1538-7445.Sabcs19-9s-04

7. Adams S, Schmid P, Rugo HS et al (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30(3):397–404. https://doi.org/10.1093/annonc/mdy1517

8. Nanda R, Liu MC, Yau C et al (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6(5):676–84

9. Schmid P, Rugo HS, Adams S et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59. https://doi.org/10.1016/S1470-2045(19)30689-30688

10. Soare GR, Soare CA (2019) Immunotherapy for breast cancer: first FDA approved regimen. Discoveries (Craiova) 7(1):e91. https://doi.org/10.15190/d.12019.15194

11. Gianni L, Huang C-S, Egle D et al (2020) Abstract GS3–04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIpaPDL1 Michelangelo randomized study. Cancer Res 80(4 Supplement):GS3–04–GS03-04. https://doi.org/10.1158/1538-7445.Sabcs19-9s-04

12. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412

13. Ahn SG, Cha YJ, Bae SJ et al (2018) Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. BMC Cancer 18(1):320. https://doi.org/10.1186/s12885-018-4228-6

14. Yoon CI, Park S, Cha YJ et al (2020) Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. Breast 50:141–148. https://doi.org/10.1016/j.breast.2019.09.013

15. Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. https://doi.org/10.1200/jco.2006.09.2775

16. Ahn SG, Dong SM, Oshima A et al (2013) LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat 141(1):89–99. https://doi.org/10.1007/s10549-10013-12662-10543

17. Emens LA, Cruz C, Eder JP et al (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5(1):74–82. https://doi.org/10.1001/jamaoncol.2018.4224

18. Cha YJ, Ahn SG, Bae SJ et al (2018) Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis. Breast Cancer Res Treat 171(2):295–302. https://doi.org/10.1007/s10549-10018-14842-10547

19. Yoon CI, Park S, Cha YJ et al (2020) Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. Breast 50:141–148. https://doi.org/10.1016/j.breast.2019.1009.1013

20. Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271. https://doi.org/10.1093/annonc/mdu1450

21. Kim SK, Ahn SG, Mun JY et al (2020) Genomic signature of the standardized uptake value in (18)F-fluorodeoxyglucose positron emission tomography in breast cancer. Cancers (Basel). https://doi.org/10.3390/cancers12020497

22. de Hoon MJ, Imoto S, Nolan J et al (2004) Open source clustering software. Bioinformatics 20(9):1453–1454. https://doi.org/10.1093/bioinformatics/bth1078

23. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116–5121. https://doi.org/10.1073/pnas.091062498

24. Garcia-Recio S, Thennavan A, East MP et al (2020) FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Invest. https://doi.org/10.1172/jci130323

25. Fan C, Prat A, Parker JS et al (2011) Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 4:3 https://doi.org/10.1186/1755-8794-1184-1183

26. da Huang W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1–13. https://doi.org/10.1093/nar/gkn923

27. da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57. https://doi.org/10.1038/nprot.2008.211

28. Chen X, Li J, Gray WH et al (2012) TNBCtype: a subtype tool for triple-negative breast cancer. Cancer Inform 11:147–56. https://doi.org/10.4137/CIN.a9983

29. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human-triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/jci1345014

30. Zhao X, Redland EA, Tibshirani R et al (2015) Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res 17(1):29. https://doi.org/10.1186/s13058-015-0520-4

31. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/jco.2008.18.1370

32. Fernandez-Martinez A, Krop IE, Hillman DW et al (2020) Survival, pathologic response, and genomics in CALGB 40601 (alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J Clin Oncol 38(35):4184–4193. https://doi.org/10.1200/jco.20.01276

33. Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033

34. Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812–830. https://doi.org/10.1016/j.immuni.2018.03.023

35. Echavarria I, Lopez-Tarruella S, Picornell A et al (2018) Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification. Clin Cancer Res 24(8):1845–1852. https://doi.org/10.1158/1078-0432.CCR-18-1912

36. Pereira B, Chin SF, Rueda OM et al (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7:11479. https://doi.org/10.1038/ncomms11479
37. Brueffer C, Vallon-Christersson J, Grabau D et al (2018) Clinical value of RNA sequencing–based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden Cancerome Analysis Network—Breast Initiative. JCO Precision Oncol. https://doi.org/10.1200/po.17.00135

38. Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67–76. https://doi.org/10.1016/s0140-6736(16)32455-2

39. Mariathasan S, Turley SJ, Nickles D et al (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548. https://doi.org/10.1038/nature25501

40. Leinonen R, Akhtar R, Birney E et al (2011) The European nucleotide archive. Nucleic Acids Res 39(9):D28–D31. https://doi.org/10.1093/nar/gkr967

41. Hollern DP, Xu N, Thennavan A et al (2019) B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179(5):1191-1206.e1121. https://doi.org/10.1016/j.cell.2019.10.1028

42. Echavarria I, López-Tarruella S, Picornell A et al (2018) Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s defined classification. Clin Cancer Res 24(8):1845–1852. https://doi.org/10.1158/1078-0432.Ccr-17-1912

43. Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812-830.e814. https://doi.org/10.1016/j.immuni.2018.03.023

44. Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/s0140-6736(13)62422-62428

45. Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966. https://doi.org/10.1200/JCO.2013.2955.0491

46. Hirsch FR, McElhinney A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase I of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12(2):208–222. https://doi.org/10.1016/j.jto.2016.1011.2228

47. Schats KA, Vre E, Schrijvers D et al (2017) Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263, E1L3N). J Clin Oncol 35(15_suppl):3028–3028. https://doi.org/10.1200/JCO.2017.35.15_suppl.3028

48. Duncan DJ, Scott M, Scorcr P et al (2019) Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAscope and immunohistochemistry. PLoS ONE 14(4):e0215393. https://doi.org/10.1371/journal.pone.0215393

49. Schats KA, Van Vre EA, De Schepper S et al (2017) Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology 70(2):253–263. https://doi.org/10.1111/his.13056

50. Guo L, Li W, Zhu X et al (2016) PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus 5(1):805. https://doi.org/10.1186/s40064-016-2513-x

51. Gupta S, Yaghoobii V, Fernandez A et al (2021) Abstract PS2-03: comparison of pathologist reads of sp142 and sp263 with quantitative measurement of protein and mRNA in triple negative breast cancer. Cancer Res. https://doi.org/10.1158/1538-7445.Sabcs20-ps2-03

52. Scheel AH, Baenfer G, Baretton G et al (2018) Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 72(3):449–459. https://doi.org/10.1111/his.13375

53. Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/s0140-6736(13)62422-62428

54. Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966. https://doi.org/10.1200/JCO.2013.2955.0491

55. Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559–569. https://doi.org/10.1200/JCO.1218.01010

56. Llo S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867. https://doi.org/10.1200/JCO.2011.1241.0902